Literature DB >> 30657379

Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data.

Nikki M Carroll1, Kate M Burniece1, Jeff Holzman1, Deanna B McQuillan1, Angela Plata1, Debra P Ritzwoller1.   

Abstract

PURPOSE: With the shift in the majority of oncology clinical care in the United States from paper records to electronic health records, researchers need efficient and validated processes to obtain accurate data about the entire treatment history of patients diagnosed with cancer. The objective of this study was to develop and validate an algorithm that is agnostic to the source of data but that can identify specific regimens in the entire course of systemic therapy treatment for patients diagnosed with breast, colorectal, or lung cancer.
METHODS: A cohort of patients with incident breast, colorectal, and lung cancer were randomly distributed into six groups. The algorithm was iteratively modified, and the performance was assessed until no additional modifications could be identified in the first three groups. The performance of the algorithm was confirmed in the three groups that remained.
RESULTS: The final model produced ranges of sensitivity between 97.2% and 100% for first-course systemic therapy across all cancers, with a false-positive rate of 0%. The algorithm matched the exact number of courses and the exact regimens of systemic therapy agents as captured by infusion, pharmacy, and procedure electronic medical record data for all courses of therapy 88% to 100% of the time.
CONCLUSION: Use of our validated algorithm that characterizes entire courses of systemic therapy treatment in patients diagnosed with breast, colorectal, and lung cancer will allow researchers in a variety of settings to conduct comparative effectiveness studies related to the uptake, safety, outcomes, and costs associated with the use of both novel and standard regimens.

Entities:  

Mesh:

Year:  2017        PMID: 30657379      PMCID: PMC7006900          DOI: 10.1200/CCI.17.00002

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  18 in total

1.  Validation of electronic data on chemotherapy and hormone therapy use in HMOs.

Authors:  Debra P Ritzwoller; Nikki Carroll; Thomas Delate; Maureen O'Keeffe-Rossetti; Paul A Fishman; Elizabeth T Loggers; Erin J Aiello Bowles; Jennifer Elston-Lafata; Mark C Hornbrook
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

2.  Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer.

Authors:  Scott D Ramsey; Jeannine S McCune; David K Blough; Cara L McDermott; Lauren Clarke; Jennifer L Malin; Sean D Sullivan
Journal:  Am J Manag Care       Date:  2010-09       Impact factor: 2.229

3.  Building a virtual cancer research organization.

Authors:  Mark C Hornbrook; Gene Hart; Jennifer L Ellis; Donald J Bachman; Gary Ansell; Sarah M Greene; Edward H Wagner; Roy Pardee; Mark M Schmidt; Ann Geiger; Amy L Butani; Terry Field; Hassan Fouayzi; Irina Miroshnik; Liyan Liu; Robert Diseker; Karen Wells; Rick Krajenta; Lois Lamerato; Christine Neslund Dudas
Journal:  J Natl Cancer Inst Monogr       Date:  2005

4.  Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.

Authors:  Elizabeth B Lamont; Lan Lan
Journal:  Med Care       Date:  2014-03       Impact factor: 2.983

5.  Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Authors:  Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Rogerio Lilenbaum; Richard L Schilsky; Nicholas A Christakis
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

6.  Second-line and third-line chemotherapy for lung cancer: use and cost.

Authors:  Scott D Ramsey; Renato G Martins; David K Blough; Lauri S Tock; Deborah Lubeck; Carolina M Reyes
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

7.  Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research.

Authors:  Erin J Aiello Bowles; Leah Tuzzio; Debra P Ritzwoller; Andrew E Williams; Tyler Ross; Edward H Wagner; Christine Neslund-Dudas; Andrea Altschuler; Virginia Quinn; Mark Hornbrook; Larissa Nekhlyudov
Journal:  Med Care       Date:  2009-10       Impact factor: 2.983

8.  Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare.

Authors:  Kaloyan A Bikov; C Daniel Mullins; Brian Seal; Eberechukwu Onukwugha; Nader Hanna
Journal:  Med Care       Date:  2015-08       Impact factor: 2.983

9.  Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.

Authors:  Sudeep Karve; Maria Lorenzo; Astra M Liepa; Lisa M Hess; James A Kaye; Brian Calingaert
Journal:  J Gastric Cancer       Date:  2015-06-30       Impact factor: 3.720

10.  The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration.

Authors:  Tyler R Ross; Daniel Ng; Jeffrey S Brown; Roy Pardee; Mark C Hornbrook; Gene Hart; John F Steiner
Journal:  EGEMS (Wash DC)       Date:  2014-03-24
View more
  7 in total

1.  HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model.

Authors:  Jeremy L Warner; Dmitry Dymshyts; Christian G Reich; Michael J Gurley; Harry Hochheiser; Zachary H Moldwin; Rimma Belenkaya; Andrew E Williams; Peter C Yang
Journal:  J Biomed Inform       Date:  2019-06-22       Impact factor: 6.317

2.  Consolidation of Cancer Registry and Administrative Claims Data on Cancer Diagnosis and Treatment in the US Military Health System.

Authors:  Yvonne L Eaglehouse; Amie B Park; Matthew W Georg; Derek W Brown; Jie Lin; Stephanie Shao; Julie A Bytnar; Craig D Shriver; Kangmin Zhu
Journal:  JCO Clin Cancer Inform       Date:  2020-10

3.  Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data.

Authors:  Gabriel A Brooks; Hajime Uno; Erin J Aiello Bowles; Alexander R Menter; Maureen O'Keeffe-Rosetti; Anna N A Tosteson; Debra P Ritzwoller; Deborah Schrag
Journal:  JCO Clin Cancer Inform       Date:  2019-04

4.  Extending the OMOP Common Data Model and Standardized Vocabularies to Support Observational Cancer Research.

Authors:  Rimma Belenkaya; Michael J Gurley; Asieh Golozar; Dmitry Dymshyts; Robert T Miller; Andrew E Williams; Shilpa Ratwani; Anastasios Siapos; Vladislav Korsik; Jeremy Warner; W Scott Campbell; Donna Rivera; Tatiana Banokina; Elizaveta Modina; Shantha Bethusamy; Henry Morgan Stewart; Meera Patel; Ruijun Chen; Thomas Falconer; Rae Woong Park; Seng Chan You; Hokyun Jeon; Soe Jeong Shin; Christian Reich
Journal:  JCO Clin Cancer Inform       Date:  2021-01

5.  Characterizing the Anticancer Treatment Trajectory and Pattern in Patients Receiving Chemotherapy for Cancer Using Harmonized Observational Databases: Retrospective Study.

Authors:  Hokyun Jeon; Seng Chan You; Seok Yun Kang; Seung In Seo; Jeremy L Warner; Rimma Belenkaya; Rae Woong Park
Journal:  JMIR Med Inform       Date:  2021-04-06

6.  Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital.

Authors:  Signe Sørup; Bianka Darvalics; Jakob Schöllhammer Knudsen; Anne Staub Rasmussen; Cathrine Fonnesbech Hjorth; Søren Viborg Vestergaard; Azza Ahmed Khalil; Leo Russo; Dina Oksen; Emmanuelle Boutmy; Patrice Verpillat; Mikael Rørth; Deirdre Cronin-Fenton
Journal:  Clin Epidemiol       Date:  2022-02-11       Impact factor: 4.790

Review 7.  Identifying options for oncology therapy regimen codification to improve standardization-combined results of an expert panel and a review.

Authors:  Robert Terkola; Christophe Bardin; Garbiñe Lizeaga Cundin; Nadine Zeinab; Mirjam Crul
Journal:  J Clin Pharm Ther       Date:  2021-03-09       Impact factor: 2.512

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.